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Abstract  27 
Aims Epigenetics may mediate the effects of environmental risk factors on disease, including 28 
heart disease. Thus, measuring the DNA methylome offers the opportunity to identify novel 29 
disease biomarkers and novel insights into disease mechanisms. The DNA methylation 30 
landscape of ascending aortic dissection (AD) and bicuspid aortic valve (BAV) with aortic 31 
aneurysmal dilatation remain uncharacterized. The present study aimed to explore the genome-32 
wide DNA methylation landscape underpinning these two diseases. 33 
Methods and results We used Illumina 450k DNA methylation beadarrays to analyze 21 34 
ascending aorta samples, including 10 cases with AD, 5 with BAV and 6 healthy controls. We 35 
adjusted for intra-sample cellular heterogeneity, providing the first unbiased genome-wide 36 
exploration of the DNA methylation landscape underpinning these two diseases. We discover that 37 
both diseases are characterized by loss of DNA methylation at non-CpG sites. We validate this 38 
non-CpG hypomethylation signature with pyrosequencing. In contrast to non-CpGs, AD and BAV 39 
exhibit distinct DNA methylation landscapes at CpG sites, with BAV characterized mainly by 40 
hypermethylation of EZH2 targets. In the case of AD, integrative DNA methylation gene 41 
expression analysis reveals that AD is characterized by a dedifferentiated smooth muscle cell 42 
phenotype. Our integrative analysis further reveals hypomethylation associated overexpression 43 
of RARA in AD, a pattern which is also seen in cells exposed to smoke toxins.  44 
Conclusion Our data supports a model in which increased cellular proliferation in AD and BAV 45 
underpins loss of methylation at non-CpG sites. Our data further supports a model, in which AD  46 
is associated with an inflammatory vascular remodeling process, possibly mediated by the 47 
epigenome and linked to environmental risk factors such as smoking. 48 
 49 
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1. Introduction 56 
Aortic dissection (AD) is the most frequently diagnosed lethal condition of the aorta, and is 57 
classified as Stanford type A if the ascending aorta is involved. Bicuspid aortic valve (BAV) is the 58 
most common congenital cardiac malformation and is frequently associated with an aortopathy 59 
manifested by aneurysmal dilatation of the ascending aorta. Aortic diseases are only diagnosed 60 
after a long period of subclinical development, at which point they present with a dissection or 61 
rupture, with an extremely poor prognosis. Furthermore, the overall global death rate from AD 62 
and aortic aneurysms has increased from 2.49 per 100 000 in 1999 to 2.78 per 100 000 63 
inhabitants in 20104, representing an increased global health burden. Underlying this increased 64 
burden is also the increased worldwide exposure to major risk factors, including notably smoking 65 
and hypertension. Thus, while risk prediction and early detection of aortic diseases remains the 66 
outstanding challenge, there is an equally urgent need to elucidate the molecular mechanisms 67 
linking the major risk factors to AD and BAV. 68 
The epigenome, and DNA methylation in particular, is a highly malleable entity, with DNAm 69 
alterations having been associated with all major disease risk factors including diet, smoking and 70 
age [Petronis A et al 2010, Teschendorff et al JAMA Onco 2015, Teschendorff et al Genome Res 71 
2010]. For instance, recent studies have identified DNAm changes in the blood of smokers which 72 
may mediate the causal link to lung cancer and which are able to predict the future risk of lung 73 
cancer [BMJ paper + Fasanelli F et al Nat Comm.2015]. While the role of DNAm alterations in 74 
cardiovascular disease is also rapidly increasing 5,6, its role (if any) in the pathogenesis of AD and 75 
BAV is unclear. 76 
Here, we decided to perform an explorative study of the DNAm landscapes underpinning AD and 77 
BAV. The comparison of AD to BAV is also of interest, as it has been proposed that BAV is not 78 
only a disorder of valvulogenesis, but also represents the co-existent abnormalities of aortic 79 
media2,3. Indeed, patients with BAV, including those with a haemodynamically normal valve, may 80 
have dilated aortic roots and ascending aortas. In addition, for AD we perform an integrative 81 
DNAm – mRNA expression analysis, using previous gene expression data of the ascending aorta 82 
of Stanford type A acute aortic dissection cases 1 83 
 84 
2. Methods 85 
2.1 Ethics statement and samples 86 
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This study was approved by the Ethics Committee of Zhongshan Hospital, Fudan University 87 
(Approval No. B2012-001) and all patients gave written informed consent. The study conforms to 88 
the principles outlined in the Declaration of Helsinki. A total of 24 ascending aortic tissue samples 89 
were collected. The 24 samples were collected from the individuals including 12 patients with 90 
acute ascending aortic dissection, 6 patients with bicuspid aortic valve associated with 91 
aneurysmal dilatation of the ascending aorta (aortic diameter >4.5 cm) and 6 organ donors. 92 
Enrollment criteria of patients with aortic dissection and method of samples harvest were 93 
previously described1. Ascending aortic tissue samples from patients with bicuspid aortic valve 94 
were similarly harvested at the time of aortic valve surgery and ascending aortic replacement. 95 
The tissue specimens used for DNA isolation were free of macroscopic thrombus or blood. Normal 96 
control samples were treated in the same manner as the test samples. Detailed clinical 97 
information of the individuals enrolled in the study is shown in table S1. 98 
 99 
2.2 DNA isolation and bisulfite modification of DNA   100 
DNA was isolated from aorta tissue using DNeasy Blood and Tissue Kit (Qiagen, Hilden, 101 
Germany) and genomic DNA was treated with sodium bisulfite using the EZ DNA Methylation kit 102 
(ZymoResearch, Irvine, CA, USA) following the protocol supplied by the manufacturer. 103 
 104 
2.3 Methylation analysis using the 450k array 105 
DNA methylation analysis using the Infinium Human-Methylation450k BeadChip (Illumina, San 106 
Diego, CA, USA) was performed according the manufactures' instruction. Raw Illumina data files 107 
were generated for further analysis. 108 
 109 
2.4 Methylation analysis using pyrosequencing 110 
Aliquots of the same genomic DNA as for microarray experiment were converted by bisulfite as 111 
previously mentioned. PCR reactions amplifying bisulfite-treated DNA for subsequent 112 
pyrosequencing analysis are performed using PyroMark PCR Kit (Qiagen, Hilden, Germany). 113 
Pyrosequencing reactions were performed using PyroMark Gold Q96 Reagent Kit (Qiagen) in 114 
PyroMark Q96 ID System (Qiagen, Hilden, Germany). PCR primers and Pyrosequencing primers 115 
were designed for 10 non-CpG loci using PyroMark Assay Design Software 2.0 (Qiagen, Hilden, 116 
5 
 
Germany). The sequence of primers are shown in table S2. All experimental processes were 117 
carried out according to the manufacturer's protocol. 118 
 119 
2.5 Preprocessing, quality control and normalization 120 
We used the “preprocessRaw” function in the R package “minfi”7 to convert raw Red/Green 121 
channel signals (idat files) into methylation signals. The “detectionP” function from the same 122 
package was used to determine coverage per probe and sample using a detection P-value 123 
threshold of 0.05. We then ran BMIQ8 to correct for type-2 probe bias.  124 
 125 
2.6 Reference DNA methylation centroid construction and cell-type deconvolution  126 
In order to obtain approximate estimates of the cellular proportions in our samples, we used 127 
Illumina 450k data from the ENCODE project9. The ENCODE 450k data was normalized with 128 
BMIQ. To identify the most relevant ENCODE cell-lines we estimated partial correlation 129 
coefficients between the DNAm profiles of our 21 aorta samples and each of the 63 ENCODE 130 
cell-lines. Partial correlations assess the similarity of each of our 21 aorta samples to each of the 131 
63 ENCODE cell-lines taking into account the correlation to all other ENCODE cell-lines. Thus a 132 
significant positive partial correlation between a sample and a given cell-line means that the cell-133 
line’s DNAm profile is highly similar to that of the sample, and that this similarity can’t be explained 134 
by the correlation to another ENCODE cell-line. ENCODE cell-lines were then ranked according 135 
to the average partial correlation over the 21 samples. In line with the expectation that aorta 136 
samples are made up primarily of aortic smooth muscle cells, fibroblasts and endothelial cells, 137 
the top 3 ranked cell-lines represented these cell-types. Specifically, the top-ranked cell-lines 138 
represent models for progenitor fibroblasts, aortic smooth muscle cells and human umbilical vein 139 
endothelial cells. Other highly ranked cell-lines represent other types of fibroblasts but were 140 
excluded due to highly similar profiles with progenitor fibroblasts. In order to construct the 141 
reference DNAm profiles (the “centroid”), we identified high-confidence differentially methylated 142 
CpGs between each pair of cell-types (6 pairwise comparisons) by ranking probes according to 143 
their difference in methylation and picking the n top-ranked probes, where n=min(50, #probes 144 
with |Δβ|>0.7). Thus, for each comparison we picked the number of probes where the difference 145 
in methylation was larger than 0.7 in absolute terms, or the top-ranked 50, whichever number was 146 
the smallest. This resulted in a centroid DNAm data matrix of 131 unique probes and 3-cell types. 147 
6 
 
With this reference centroid, and for an independent sample with a 450k DNAm profile, the 148 
proportions of the underlying cell-types was estimated using Houseman’s CP algorithm10. 149 
 150 
2.7 Unsupervised analysis using SVD  151 
Random Matrix Theory (RMT)11 and Singular Value Decomposition (SVD) was used to assess 152 
the number and nature of the significant components of variation in the data. Significant 153 
components of variation were then correlated with biological phenotypes, including age, disease 154 
status, and the cell type proportions estimated using the Houseman CP algorithm. Age and cell-155 
type proportions were treated as continuous variables and linear regression was used, whereas 156 
disease status (H, AD, BAV) was treated as categorical and so a Kruskal-Wallis test was used. 157 
This unsupervised analysis was performed in both the beta and M-value (M=log2(β/(1-β)) basis.  158 
 159 
2.8 Differential DNA methylation analysis 160 
Due to the small sample size of our study, and therefore the need to use empirical Bayes methods 161 
for calling differential methylation12, beta values were converted to M-values, since M-values are 162 
less heteroscedastic and therefore conform better to the Gaussian assumption underlying the 163 
empirical Bayes model. Differential methylation was called at the probe-level on the M-valued 164 
PC1-adjusted data using an empirical Bayesian framework as implemented in the R package 165 
“Limma”13. This allowed us to detect differentially methylated CpGs (DMCs) between every pair 166 
of phenotypic comparisons. False Discovery Rate (FDR) was used to correct P-values for multiple 167 
testing and a threshold of FDR<0.15 was used to declare statistical significance. We note that we 168 
relaxed the threshold of significance since in some cases no DMC passed a threshold of 0.05. 169 
This is still acceptable since in our experience FDR thresholds of even <0.3 can lead to molecular 170 
signatures that can be validated in external data14. In our case, an FDR<0.15 means that a DMC 171 
has an approximately 15% change of being a false positive, so an 85% change of being a true 172 
positive. 173 
 174 
2.10 Integration of DNA methylation and mRNA expression  175 
Our previous study reported 1152 differentially expressed genes (DEGs) between AD cases and 176 
healthy controls1. For each of these DEGs, we selected all differentially methylated probes 177 
between AD and H (at FDR < 0.3) that mapped to this gene. 178 
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 179 
2.11 Enrichment of ChIP-Seq histone signals and transcription factor binding site analysis  180 
Fully processed Roadmap epigenomics histone mark data were downloaded 181 
from http://egg2.wustl.edu/roadmap/data/byFileType/peaks/consolidated/broadPeak. We used 182 
bedtools15 to evaluate overlap with 450k array probes. For each probe overlap with a given 183 
genomic element was coded as one, and no overlap was coded as zero. Extended documentation 184 
on how to rebuild the database from scratch, as well as the code used, is available 185 
in https://github.com/charlesbreeze/eFORGE/tree/master/database. 186 
For the transcription factor binding site analysis, we followed the same procedure as in our 187 
previous publication16. For a given list of DMCs, these were split into hypermethylated and 188 
hypomethylated subsets, and enrichment  for transcription factor  binding sites or for  histone 189 
marks determined using a  one-tailed Fisher exact test. 190 
2.12 Enrichment analysis against age-DMCs 191 
To test for enrichment of AD and BAV associated DMCs for sites undergoing differential 192 
methylation with age, we identified age-DMCs from a large (n>560 samples) Illumina 450k EWAS 193 
for aging conducted in whole blood [Hannum et al Mol.Cell.2014]. The age-DMCs were derived 194 
using a very stringent procedure which adjusted for sex, ethnicity, plate effects and changes in 195 
blood-cell type composition [Yuan T , Teschendorff AE PLoS Genetics 2015]. A total of 70,249 196 
CpGs passed an FDR<0.05, of which 31,217 were hypermethyated with age, and 39,032 were 197 
hypomethylated with age. For the given set of AD-DMCs (or BAV-DMCs) we asked how many of 198 
these were significantly associated with age in Hannum et al, taking into account directionality of 199 
methylation change, which is important to consider since AD (or BAV) cases are older than 200 
controls. Thus, for AD (and separately for BAV) we obtain a  2 x 2 matrix of counts, representing 201 
the number of hypermethylated and hypomethylated AD-DMCs (or BAV-DMCs) which are 202 
hypermethylated or hypomethylated with age. Odds ratio and P-value of enrichment was then 203 
computed using a one-tailed Fisher’s exact test. 204 
 205 
 206 
3. Results 207 
3.1 Unsupervised analysis captures DNAm variation associated with AD and BAV 208 
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We performed Illumina 450k DNAm profiling on a total of 6 ascending aorta samples from healthy 209 
individuals, 12 samples from ascending aortic dissection (AD) cases and another 6 samples from 210 
patients with bicuspid aortic valve (BAV) associated with ascending aortic aneurysmal dilatation. 211 
Data underwent a stringent quality control (QC) procedure, including normalization for type-2 212 
probe design bias, as performed by us in previous studies17, resulting in 484,724 usable probes. 213 
All 6 healthy samples were from males, with the 12 AD cases coming from 10 males and 2 214 
females, whereas 5 out of 6 BAV cases were from males (Table S1). Hence, in order to avoid 215 
confounding by sex, we only retained the 21 male samples for further analysis. Singular Value 216 
Decomposition of the 484,724 x 21 data matrix, and using permutations to estimate the number 217 
of significant components, revealed 4 significantly variable singular vectors (SVs) (or principal 218 
components-PCs) (Figure 1A).The top PC accounted for over 35% of the total data variation, with 219 
PC-2 and PC-3 accounting for approximately 7-8% of total data variation (Figure 1A). PC-1 did 220 
not correlate with disease status or age (Figure 1C), but we hypothesized that it might correlate 221 
with intra-sample cellular heterogeneity18. Since aorta samples are expected to be made up 222 
mainly of smooth muscle cells, fibroblasts and endothelial cells, we used Illumina 450k data of 223 
representative cell-lines from ENCODE9 to construct a reference DNA methylation centroid from 224 
which we then estimated cell-type fractions in individual samples using the Houseman CP 225 
algorithm10. To identify the most relevant ENCODE cell-lines, we computed partial correlations of 226 
each sample’s DNAm profile to the corresponding DNAm profile of each of 63 ENCODE cell-lines 227 
(Methods). This showed that a progenitor fibroblast (ProgFib), an aortic smooth muscle cell 228 
(AoSMC), and human umbilical vein endothelial cells (HUVEC) were the most representative cell-229 
lines for modelling aortic smooth muscle cells, fibroblasts and endothelial cells present in our 230 
samples (Figure 1B). Confirming our expectation, estimated fractions for these 3 cell-types 231 
correlated strongly with PC-1 (and only with PC-1) (Figure 1C). Specifically, we observed that the 232 
proportion of AoSMC-like cells decreased in AD cases, whereas the endothelial cell-like 233 
proportion increased (Figure S1). PC-2 correlated marginally with disease status and age (Figure 234 
1C). Since AD and BAV cases were significantly older (Figure S2) than the healthy controls, we 235 
interpret PC-2 mainly as an age-driven component. Attesting to the quality of our data, Horvath’s 236 
DNAm-Age19 correlated significantly with chronological age (PCC=0.62, P=0.003), despite the 237 
relatively small sample size (Figure S3). Interestingly, all samples except one normal sample, 238 
exhibited age-acceleration, but with AD and BAV cases however exhibiting less age-acceleration 239 
than the healthy samples (Figure S3).  PC-3 correlated only with disease status, and was specially 240 
prominent discriminating AD from BAV cases, although interestingly it also discriminated both 241 
types of disease from healthy controls (Figure 1D). Given that PC-1 captures variation associated 242 
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with cellular heterogeneity, and that age is an important predictor of outcome in AD and BAV2,20, 243 
we decided to adjust the data for PC-1 only, by regressing this component out of the data prior to 244 
the supervised analysis.  245 
 246 
3.2 Supervised analysis reveals a non-CpG hypomethylation signature associated with AD 247 
and BAV 248 
Applying an empirical Bayesian framework, which works optimally in a small sample size setting12, 249 
to the PC1-adjusted data matrix, we inferred a total of 706 differentially methylated cytosines 250 
(DMCs) between AD and H, 3775 between BAV and H, and a total of 12817 DMCs between BAV 251 
and AD (Figure 2A, table S3). Although AD cases were notably older than controls (table S1), 252 
among the corresponding DMCs we did not observe an enrichment for age-associated DMCs 253 
(Methods, [Hannum et al Mol Cell 2014]), in contrast to BAV-associated DMCs which did exhibit 254 
such an enrichment (Figure S4). Of the 706 DMCs between AD and H, 396 (56%) were 255 
hypermethylated in AD compared to H. Among the 3775 DMCs between BAV and H, 1979 (52%) 256 
were hypermethylated in BAV compared to H (Figure 2B). Over 75% of the 12817 DMCs between 257 
BAV and AD were hypomethylated in BAV compared to AD. Intriguingly, in the AD-H comparison, 258 
we observed a 34-fold enrichment of non-CpGs (n=122, Fisher-test, P<1e-100) among the 706 259 
DMCs, with this non-CpG overenrichment being less significant in the case of BAV-H and non-260 
existent between BAV and AD (Figure 2C). A heatmap of relative methylation values over the 122 261 
non-CpG DMCs between AD and H revealed that effectively all of these sites lost methylation in 262 
AD cases compared to healthy controls (Figure 2D). Of note, these sites also lost methylation in 263 
BAV cases (Figure 2D).  264 
In order to shed light on the nature of this non-CpG hypomethylation signature, we asked if there 265 
was a specific bias in terms of the sequence context of the non-CpGs21. Comparing the relative 266 
occurrence of [CA]C vs [CA]G sequence among our 122 non-CpGs, we observed a striking 267 
enrichment for the [CA]C context (Table 1).  268 
Table 1 Sequence context enrichment table of significantly hypomethylated non-CpGs for each of the 269 
three comparisons: AD vs Healthy, BAV vs Healthy and BAV vs AD. 270 
 [CA]C  [CA]G 
 Count Exp. Count OR P-value  Count Exp. Count OR P-value 
AD vs. Healthy 39 6.79 9.99(6.39,15.44) <2E-16  76 102.88 0.29(0.19,0.43) 1.79E-009 
BAV vs. Healthy 21 6.9 3.8(2.19,6.32) 2.73E-006  98 104.57 0.69(0.44,1.12) 0.1 
10 
 
BAV vs. AD 0 1.45 0(0.00,2.59) 0.4  21 21.92 0.78(0.28,2.66) 0.59 
OR and P-value estimated by Fisher's Exact Test. 271 
 272 
3.3 Technical validation of the non-CpG hypomethylation signature using pyrosequencing 273 
In order to further test the reliability of the data, we decided to validate the non-CpG 274 
hypomethylation signature in AD cases using the gold-standard procedure of pyrosequencing. 275 
We randomly picked 10 of the top ranked non-CpG probes exhibiting hypomethylation in AD 276 
cases vs healthy controls (H) according to the Illumina 450k assay, and for these loci we assessed 277 
DNA methylation using pyrosequencing in a subset of 6 H and 6 AD cases (a subset of the original 278 
samples used in the discovery). All 10 non-CpG loci exhibited significant hypomethylation in AD 279 
cases, thus validating the Illumina results (Figure 3A). Further attesting to the quality of the data, 280 
we observed very strong correlations between the DNAm values obtained using Illumina 450k 281 
and pyrosequencing when assessed in the 6 healthy controls (Figure 3B, Figure S5) 282 
 283 
3.4 Different chromatin enrichment patterns for AD and BAV 284 
In order to gain further insight into putative epigenetic mechanisms underlying BAV or AD disease, 285 
we asked if probes hypermethylated or hypomethylated in AD/BAV are enriched for specific 286 
histone marks. We obtained ChIP-Seq histone mark profiles for 5 major marks (H3K27me3, 287 
H3K4me3, H3K4me1, H3K36me3 and H3K9me3) in a surrogate cell-type (fetal heart) from the 288 
NIH Epigenomics Roadmap. For the enrichment analysis, we selected the top 5000 289 
hypermethylated and 5000 hypomethylated CpGs for each of the 3 pairwise comparisons (AD vs 290 
H, BAV vs H and BAV vs AD), which all passed a FDR threshold of 0.3. Among hypermethylated 291 
probes we observed a massive enrichment of the repressive H3K27me3 mark, which was 292 
specially prominent in BAV disease compared to either healthy controls or AD cases (Figure 4A). 293 
In contrast, the most striking enrichment when comparing AD cases to controls was seen for the 294 
H3K4me1 and H3K36me3 marks among probes hypomethylated in AD cases. Since the histone 295 
methyltransferase EZH2 catalyzes H3K27me3 and also acts as a recruitment platform for DNA 296 
methyltransferases (DNMTs), these results suggest that BAV disease may be characterized by 297 
increased activity of EZH2. To check this we used ChIP-Seq from ENCODE for a total of 58 TFs, 298 
albeit in a different cell-type (hESCs). Confirming our hypothesis, we observed strong enrichment 299 
(Fisher test P<1e-50) of EZH2, SUZ12 (another member of the PRC2 complex) and CtBP2 among 300 
CpGs hypermethylated in BAV disease compared to controls, but no such enrichment among 301 
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hypomethylated CpGs (Figure 4B). Comparing AD to H, we only observed enrichment (Fisher 302 
test P<1e-6) for two TFs (BCL11A and POU5F1) among hypermethylated CpGs (Figure 4B), with 303 
no enrichment among hypomethylated sites, suggesting that binding of BCL11A and POU5F1 304 
may be disrupted in AD.  305 
 306 
3.5 Integration of DNA methylation and mRNA expression reveals downregulation of 307 
smooth muscle genes and targets of smooth muscle differentiation factors in AD 308 
We previously performed mRNA expression profiling of 5 healthy individuals and 7 AD cases1. 309 
Thus, we aimed to identify genes showing both significant differential methylation and differential 310 
gene expression between AD and H. Anchoring the analysis on 1152 differentially expressed 311 
genes (DEGs) at FDR < 0.05, we identified a total of 254 unique DEGs with at least 1 probe 312 
exhibiting significant differential methylation (at FDR < 0.3) (Table S4). Of these 254 unique 313 
DEGs, 138 were overexpressed in AD compared to H, and 116 underexpressed. We performed 314 
GSEA separately on these over and underexpressed genes. While genes overexpressed in AD 315 
were enriched for cellular proliferation, genes underexpressed in AD were enriched for many 316 
biological terms highly relevant to AD disease (Table S5). For instance, we observed many genes 317 
(e.g. CALD1, MRVI1, ADCY9, PLCB4, ACTG2, RAMP1, ADRA1B) implicated in vascular smooth 318 
muscle contraction. Also, many of these genes, as well as other genes (e.g. MBNL1, DACT3, 319 
LDB3, DMPK, LPP) are targets of SRF, a well-known differentiation factor for smooth muscle 320 
cells22. Downregulated SRF targets (e.g. CALD1 or DACT3) had probes near their TSS which 321 
exhibited hypermethylation, although this pattern was not evident for all (Figure S6). Likewise, we 322 
observed enrichment of many targets of a MYOD TF binding motif, implicating downregulation of 323 
MYOD1 targets (e.g. MEF2D, GRK5, FAM107B) in AD. In addition, we observed enrichment of 4 324 
genes (ADCY9, HRK5, FAM129A and CRIM1) which have been reported to be also 325 
downregulated in unstable atherosclerotic plaque23, 3 additional smooth muscle genes (MYOZ2, 326 
DES and MYOM1) and enrichment of 8 genes (LDB3, KANK1, FAM129A, SORBS2, LATS2, 327 
ZBTB20, FOXN3, ZNF295) which have been previously shown to be underexpressed in samples 328 
with systolic heart failure24. Furthermore, we observed that MYH11, MYOCD and SRF, all 329 
implicated in specifying a differentiated contractile SMC phenotype25, were all significantly 330 
downregulated in AD cases compared to healthy controls (Figure 5A). Confirming this, we 331 
observed a concomitant increase of signaling entropy26, a molecular correlate of dedifferentiation 332 
and cellular plasticity, in AD cases (Figure 5B). 333 
12 
 
To further test whether AD represents a departure from a normal differentiated SMC phenotype, 334 
we compared the DNAm profile of our samples to those of normal AoSMCs, as profiled by 335 
ENCODE and the NIH Epigenomics Roadmap. This confirmed that AD cases deviated more from 336 
AoSMCs than the normal samples (Figure 5C). Interestingly, however, BAV cases did not show 337 
significant DNAm deviations from AoSMCs (Figure 5C). Thus, even though there were 338 
significantly more DMCs between BAV and H than between AD and H (Figure 2A), when 339 
comparing AD and BAV to AoSMCs, only AD showed significant DNAm deviations (Figure 5C).  340 
 341 
3.6 Hypomethylation of RARA in AD and smoking 342 
Smoking is a major risk factor for AD and a recent meta-EWAS has identified a number of gene 343 
loci reproducibly associated with smoking exposure in blood [Gao X, Jia M, Zhang Y, Breitling LP 344 
and Brenner H. Clin Epigenetics 2015 Oct 16;7:113]. Thus, we asked if any of our AD-associated 345 
DMCs for which the linked gene also exhibits differential expression, were among gene loci where 346 
DNAm has been associated with smoking. Notably, this revealed two specific probes which map 347 
to the retinoic acid receptor alpha (RARA) gene (Table S4), which has been shown to undergo 348 
differential methylation in response to smoking in several EWAS conducted in blood.  Specifically, 349 
we identified two probes hypomethylated in AD cases (Table S4) which also exhibit 350 
hypomethylation in cells exposed to smoke toxins [Gao X, Jia M, Zhang Y, Breitling LP and 351 
Brenner H. Clin Epigenetics 2015 Oct 16;7:113] . One probe mapped to within 200bp of the TSS 352 
of RARA, while the other probe mapped to the 5’UTR. Although none of the 2 probes correlated 353 
with smoking status in our AD cases and controls (Figure S7), when we tested these 2 probes in 354 
3 large EWAS studies of smoking, one conducted in buccal epithelium17 and two conducted in 355 
blood27,28, we did observe that the probe mapping to the 5’UTR exhibited significant 356 
hypomethylation in smokers compared to non-smokers in all 3 studies (Figure S8). Thus, this 357 
constitutes the first report of a common molecular alteration (DNA hypomethylation) which is seen 358 
in relation to both smoking and AD. 359 
 360 
3.7 Genes implicated in BAV exhibit more frequent differential methylation in BAV 361 
Genes found mutated in BAV have previously been reported29. We asked if differential 362 
methylation around these sites is more frequently observed in BAV compared to a random set of 363 
sites. For the 9 genes (NOTCH1, AXIN1, EGFR, ENG, GATA5, NKX2-5, NOS3, PDIA2, and 364 
13 
 
TGFBR2) implicated in BAV, we identified a total of 333 CpGs mapping to them. We observed 365 
that these 333 CpGs exhibited significantly larger absolute t-statistics of differential methylation 366 
as compared to CpGs mapping to a randomly selected set of 500 genes (excluding BAV-related 367 
genes) (P< 0.0001 from a Wilcoxon-rank sum test, Figure S9). In fact, we observed almost twice 368 
as many DMCs mapping to BAV-related genes than what would have been expected by random 369 
chance (Binomial test P<1e-5, Figure S9).  370 
 371 
4. Discussion 372 
4.1 Significant non-CpG methylation in the ascending aorta 373 
The first important finding of our study is the significant non-CpG methylation within the ascending 374 
aorta and the subsequent loss of methylation at these sites in AD and BAV. The first observation 375 
is consistent with a recent study reporting detectable levels of non-CpG methylation in 2 donor 376 
aorta samples31.  Interestingly, among non-CpGs with high methylation levels in normal aorta, we 377 
observed an enrichment for a [CA]C context, which is similar to that seen in adult brain tissues32,33 378 
.This is noteworthy given that previous studies have revealed non-CpG methylation to be 379 
abundant only in pluripotent cells and brain cells 30. Importantly, it has been demonstrated that 380 
during development of the mammalian cardiovascular system, the smooth muscle of the 381 
ascending aorta derives from the cardiac neural crest34. This contribution of the neural crest to 382 
the ascending aortic smooth muscle is unusual as most smooth muscle is derived from the 383 
mesoderm, yet it clearly indicates a developmental link between this specific area of the aorta 384 
and the neural system, which may explain the observed non-CpG methylation in our aorta 385 
samples. Furthermore, for non-CpG methylation to be maintained, it would need to be re-386 
established de novo after each cell division, yet there is no known maintenance mechanism for 387 
DNAm at non-CpG sites. Thus, in most cell types non-CpG methylation is rapidly lost following 388 
cell division, except in infrequently dividing cells such as neurons21. Like neurons, differentiated 389 
SMCs in adult blood vessels proliferate at an extremely low rate. Thus, the loss of methylation at 390 
non-CpGs observed in AD and BAV could be due to abnormally proliferating SMCs, consistent 391 
with the observed higher expression of cell-proliferation genes. Some reports have also provided 392 
evidence that non-CpG methylation could have a functional role in biological and pathological 393 
processes, such as genomic imprinting32, somatic cell reprogramming35, brain development36, 394 
Rett syndrome37, diabetes38 and obesity39. Although we don’t have any data to support that the 395 
observed hypomethylation at non-CpGs is of functional consequence, it will be interesting for 396 
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future studies to investigate if the non-CpG methylation in the ascending aorta has a direct 397 
functional consequence in aortopathy. Regardless of a functional effect or not, our finding of a 398 
strong non-CpG hypomethylation signature in ascending aortic dissection and aortic aneurysmal 399 
dilatation with BAV hints at a potential future application of non-CpG methylation as an epigenetic 400 
biomarker. 401 
4.2 AD is characterized by a dedifferentiated smooth muscle cell phenotype  402 
Our second important finding is that of a dedifferentiated smooth muscle cell phenotype, as a key 403 
feature of AD. Smooth muscle cells are thought to be the major cell type in the aorta and display 404 
a remarkable plasticity undergoing phenotype changes in response to environmental cues. 405 
Differentiated SMCs express contractile marker genes such as MYH11, MYOCD and SRF. In our 406 
study, the integration of DNA methylation and mRNA expression in AD revealed downregulation 407 
of smooth muscle genes and targets of smooth muscle differentiation factors (e.g. SRF), while 408 
genes overexpressed in AD were enriched for cellular proliferation, suggesting that SMCs in AD 409 
underwent dedifferentiation. We note that all of these results were obtained after correction for 410 
cell-type composition changes, strongly supporting the view of a dedifferentiated SMC phenotype 411 
as the most likely mechanism underlying the observed DNAm changes in AD. That is, even 412 
though the proportion of AoSMC-like cells decreased in AD, this by itself does not seem to explain 413 
all observed patterns of DNAm alteration in AD. Although the phenotypic plasticity exhibited by 414 
mature SMCs confers an advantage during repair of vascular injury, this plasticity can also induce 415 
adverse phenotypic switching and contribute to the development and progression of vascular 416 
diseases40-42. Our integrated data is indicative of such a kind of adverse phenotypic switching of 417 
SMCs affecting the contractile function in AD. In advanced atherosclerotic plaques, SMCs may 418 
play either a beneficial role or a detrimental role in determining plaque stability, depending on the 419 
phenotypic state43. The downregulation of genes in AD which are also downregulated in unstable 420 
atherosclerotic plaque further suggests that phenotypic changes in AD may be contributing to the 421 
instability of the aortic wall and the end-stage disease event of dissection. Other studies have 422 
associated vascular inflammatory response with vascular dysfunction and disease, with 423 
inflammatory cytokines interacting with SMCs through specific receptors to promote cell growth 424 
and migration, which impacts on vascular smooth muscle reactivity44,45. Given that our previous 425 
mRNA expression study revealed a vascular inflammatory process characterized by 426 
overexpressed cytokines and receptors in AD, this supports a model of interaction between 427 
inflammatory response and vascular function in the disease. 428 
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4.3 Epigenome mediates phenotypic alteration linking to environmental risk factors such 429 
as smoking in AD 430 
Smoking has been identified to be a critical risk factor for acute aortic dissection20 and has been 431 
associated with durable alterations in vascular smooth muscle cell and inflammatory cell 432 
function46,47. Interestingly, RARA has previously been associated with smoking-associated 433 
differential methylation in blood27,28 and was also among the genes exhibiting significant 434 
differential methylation and differential expression in AD. We further demonstrated that a specific 435 
probe undergoing hypomethylation in AD also undergoes smoking-associated hypomethylation 436 
in blood and buccal tissue, suggesting that this smoking-associated hypomethylation may be valid 437 
in any cell which comes into direct exposure with smoke toxins. Of note, the observed 438 
hypomethylation in our AD cases could not be attributed to their increased smoking exposure, as 439 
smokers and non-smokers exhibited similar levels of RARA methylation in both AD cases and 440 
controls. Thus, our study demonstrates a common molecular alteration in smoking and AD. In 441 
summary, our integrative DNAm-mRNA expression based approach suggests that AD is defined 442 
by a dedifferentiated phenotypic alteration in SMCs, probably associated with an impaired 443 
contractile function of SMCs and weakening of the aortic wall, itself suggestive of a vascular 444 
pathological process that occurs in response to environmental cues such as smoking (Figure 6). 445 
4.4 AD and BAV with aortic aneurysmal dilatation exhibit distinct DNA methylomes 446 
Our study has further demonstrated that BAV and AD exhibit different epigenetic profiles, 447 
supporting the view that these represent two very different pathological conditions. Indeed, there 448 
is ample evidence that BAV associated with aortic insufficiency has a genetic origin and a higher 449 
risk of adverse aortic complications irrespective of the extent of valvular disease48. However, the 450 
underlying genetic origins and epigenetic pathways predisposing to aortopathy remain to be 451 
demonstrated. Our results revealed that while BAV with aortic aneurysmal dilatation had more 452 
DMCs than AD, that its global DNAm profile did not deviate appreciably from normal AoSMCs. 453 
Interestingly, we observed that many of the hypermethylated DMCs characterizing BAV appear 454 
to occur at PRC2/EZH2 binding sites suggesting increased DNMT and repressor activity. Of note, 455 
we observed that CpGs mapping to genes previously found mutated in BAV, were almost twice 456 
as likely to be differentially methylated in BAV than a random set of CpGs. Although we did not 457 
assess here whether these DNAm changes were functional, it will be exciting to explore this 458 
further and assess whether epigenetically mediated dysfunction of these genes provides an 459 
alternative pathway to BAV pathogenesis. In summary, our data points towards widely different 460 
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altered epigenetic landscapes underlying BAV and AD, although the diseases themselves may 461 
exhibit similar complications such as aortic rupture.  462 
4.5 Limitations 463 
It is important to emphasize the main limitations of our study. First, the small sample size of our 464 
study and the lack of an independent validation set, means that our results must be interpreted 465 
with caution. Nevertheless, many of our results (e.g. the hypomethylation at non-CpGs in AD) are 466 
strongly consistent with known biology and were validated with an independent platform (i.e. 467 
pyrosequencing), indicating that the DNAm changes seen in this study are not artifacts. Second, 468 
cases and controls were not age-matched, and even though they were matched for smoking 469 
status, the differences in age means that cases and controls may have had different lifetime 470 
exposures to smoking. Nevertheless, we did not observe any evidence of confounding by age or 471 
smoking in AD, as AD-associated DMCs were not enriched for age-associated or smoking-472 
associated DMCs. Moreover, the observed hypomethylation at non-CpGs is clearly not an age-473 
associated or smoking-associated signature as no study has reported such a signature in relation 474 
to age [Teschendorff AE et al Hum Mol Genet 2013] or smoking [Gao X, Jia M, Zhang Y, Breitling 475 
LP and Brenner H. Clin Epigenetics 2015 Oct 16;7:113]. In contrast, for BAV we did observe an 476 
enrichment for age-associated DMCs, which may partly explain the larger number of DMCs 477 
between cases and controls, and the observed enrichment for hypermethylated at repressive 478 
chromatin marks including H3K27me3, EZH2 and SUZ12. 479 
It could be argued that a third limitation of our study is the use of (ENCODE) cell-lines to adjust 480 
for cell-type composition.  Although it is clear that cell-lines are limited as models of representative 481 
cell-types in-vivo, it is worth pointing out that DNAm profiles of such cell-lines have already been 482 
successfully used for performing cell-type deconvolution in other complex tissues such as 483 
breast49,50. The reason why cell-lines may indeed be appropriate for cell-type deconvolution is that 484 
the deconvolution itself is only performed using sites which exhibit large differences in DNAm 485 
between the underlying cell-types (typically over 80% changes in DNAm). Thus, although cell-486 
lines are subject to cell-culture in-vitro effects, which undoubtedly change the DNAm landscape, 487 
it is unlikely however that these in-vitro effects would cause massive i.e. over 80% changes in 488 
DNAm. Thus, reference DNAm profiles derived from cell-line models provides a reasonable 489 
approach to estimate cell-type fractions in complex tissues. A key priority for future studies 490 
however, will be the generation of DNAm profiles of purified primary cell populations representing 491 
the relevant cell-types in aorta samples. 492 
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 493 
4.6 Conclusions and perspectives 494 
To conclude, we have performed the first explorative study of the DNAm landscape underpinning 495 
AD and BAV. Both AD and BAV are characterized by a non-CpG hypomethylation signature, 496 
which we posit reflects the increased cellular proliferation seen in both diseases. However, in 497 
general, both diseases exhibit widely different DNAm landscapes, with BAV characterized mainly 498 
by hypermethylation at sites marked by repressive chromatin, while AD is characterized by a 499 
dedifferentiated smooth muscle cell phenotype. Future studies will need to determine the causes 500 
of this phenotype switch in AD and whether DNAm alterations contribute to it. Of particular interest 501 
will be to investigate the role of DNA methylation alterations as a causal link between smoking 502 
and AD.   503 
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 638 
Figure Legends 639 
Figure 1 DNA methylation variation correlates with AD and BAV. (A) Plot of the fraction of 640 
variation (fVAR, y-axis) explained by the 21 PCs from a SVD on the DNAm data matrix (red-641 
points). The corresponding fraction of variation explained by PCs inferred from a scrambled-up 642 
DNAm data matrix, representing the null distribution, is shown in green. There are 4 components 643 
with more observed variation than expected by random chance. (B) Heatmap of partial 644 
correlations of DNAm profiles between the 21 samples (y-axis) and each of 63 ENCODE cell-645 
lines (x-axis) with cell-lines sorted according to their average partial correlation (pCor). Absolute 646 
partial correlation values larger than 0.05 are statistically significant. (C) Heatmap of P-values of 647 
association between the 4 significant PCs and biological factors, including Age, Disease (BAV, 648 
AD and H) Status (Status) and estimates of cell-type proportions using aortic smooth muscle cell 649 
(AoSMC), progenitor fibroblast (ProgFib) and human umbilical vein endothelial cell (HUVEC). All 650 
P-values are estimated with an ANOVA linear model. (D) Boxplot of the weight in PC3 versus 651 
Disease Status. P-value is from a Kruskal-Wallis test. 652 
  653 
Figure 2 Supervised analysis reveals DNAm signatures associated with AD and BAV. (A) 654 
Histograms of P-values (from moderated t-tests) for the 3 comparisons (AD - H, BAV - H, BAV-655 
AD). Number of DMCs passing a FDR < 0.15 are given. (B) Fraction of DMCs identified in A) 656 
which exhibit hypermethylation and hypomethylation, for each of the 3 comparisons. For instance, 657 
there are almost 60% DMCs hypermethylated in AD compared to H. (C) Fraction of DMCs 658 
mapping to non-CpG sites for each comparison. Observed (ObsF) versus expected (ExpF) 659 
fractions are shown, together with the odds ratio (OR) and Fisher-test P-value. (D) Heatmap of 660 
relative, standardized methylation values for the 122 non-CpG DMCs between AD and H, across 661 
the 21 samples, grouped according to their disease status. 662 
 663 
Figure 3 Technical validation of hypomethylated non-CpGs in AD cases. (A) Plots of selected top 664 
10 non-CpGs DNA methylation values obtained using pyrosequencing between 6 AD cases and 665 
6 healthy controls (H). P-values are from a one-tailed Wilcoxon rank sum test. (B) Scatterplot of 666 
the DNA methylation value obtained using pyrosequencing against the Illumina 450K value for all 667 
10 selected non-CpGs, indicated in different colors. For each non-CpG we show the 6 values in 668 
the healthy controls. Average R-squared value for each non-CpG from Pearson's Correlation is 669 
provided. P-value is from a combined Fisher-test meta-analysis over all 10 non-CpGs. 670 
 671 
Figure 4 Enrichment analysis of histone marks and transcription factor binding sites. (A) Odds 672 
Ratios (OR) of enrichment of histone marks among the top 5000 hypermethylated and 5000 673 
hypomethylated CpGs (FDR < 0.3) for each of the 3 comparisons: AD vs H, BAV vs H, and BAV 674 
vs AD. For instance, for AD-H comparison, hypermethylated DMCs have higher methylation in 675 
AD vs H. Those ORs which were highly statistically significant are indicated with Fisher-test P-676 
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values. (B) As A), but now for ChIP-Seq TF binding sites for TFs which were strongly enriched in 677 
any of 3 comparisons, as indicated. Enrichment P-values < 1e-6 are indicated. 678 
 679 
Figure 5 AD associates with a loss of smooth muscle cell phenotype. (A) Boxplots comparing 680 
mRNA expression levels of 3 key genes specifying a differentiated contractile SMC phenotype, 681 
between AD cases and healthy controls. P-values are from a one-tailed Wilcoxon rank sum test. 682 
(B) Boxplot of the signaling entropy rate (SR/maxSR) between AD cases and healthy controls 683 
(H). P-value is from a one-tailed Wilcoxon rank sum test. (C) Genome-wide similarity of the DNAm 684 
profile of the samples with the DNAm profile of AoSMCs, with samples grouped according to 685 
disease status. P-value is from a one-tailed Wilcoxon rank sum test between H and AD (red), and 686 
between H and BAV (blue). Left panel is for a similarity measure derived using the Manhattan 687 
Distance between the DNAm profiles of the samples and the profile of AoSMCs. Right panel is 688 
for the Pearson Correlation Coefficient (PCC) between the DNAm profiles of the samples and that 689 
of AoSMCs. 690 
 691 
Figure 6 Epigenome mediates dedifferentiated SMC phenotype alteration in AD in response to 692 
environmental risk factors such as smoking. Environmental risk factors such as smoking links to 693 
inflammatory vascular remodeling process with increased pathological cell proliferation 694 
underpinning the loss of non-CpG methylation and a dedifferentiated SMC phenotype associated 695 
with impaired contractile function. Genes hypermethylated/downregulated are enriched in 696 
Vascular Smooth Muscle Contraction Pathway in AD.  697 
